Arcus Biosciences (RCUS) Net Margin (2017 - 2026)
Arcus Biosciences' quarterly Net Margin came in at 752.94% in Q1 2026, down 35294.0% year-on-year from N/an in Q1 2025, and down 134.41% quarter-over-quarter from 321.21% in Q4 2025.
Arcus Biosciences has reported Net Margin for 10 years, with the latest figure at 752.94% in Q1 2026.
- For the quarter ending Q1 2026, Net Margin fell 35294.0% year-over-year to 752.94%; the trailing twelve-month figure through Mar 2026 stood at 156.36% (up 12095.0% YoY), and the FY2025 full-year result was 142.91%, down 3323.0% from the prior year.
- Net Margin for Q1 2026 stood at 752.94%, down from 321.21% in the prior quarter.
- The five-year high for Net Margin was 2.76% in Q1 2024, with the low at 752.94% in Q1 2026.
- Average Net Margin over 5 years is 324.18%, with a median of 289.31% recorded in 2023.
- Year-over-year, Net Margin surged 62720 bps in 2022 and tumbled 39724 bps in 2025.
- Tracing RCUS's Net Margin over 5 years: stood at 197.06% in 2022, then tumbled by 194 bps to 578.57% in 2023, then surged by 38 bps to 361.54% in 2024, then increased by 11 bps to 321.21% in 2025, then plunged by 134 bps to 752.94% in 2026.
- The last three Net Margin figures came in at 752.94% (Q1 2026), 321.21% (Q4 2025), and 519.23% (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 0.82% |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 34.53% |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 20.17% |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 17.65% |
| 10 | Arcus Biosciences | 3.18 Bn | 2.36 Bn | - | -752.94% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -752.94% |
| Dec 31, 2025 | -321.21% |
| Sep 30, 2025 | -519.23% |
| Mar 31, 2025 | -400.00% |
| Dec 31, 2024 | -361.54% |
| Sep 30, 2024 | -191.67% |
| Jun 30, 2024 | -238.46% |
| Mar 31, 2024 | -2.76% |
| Dec 31, 2023 | -578.57% |
| Sep 30, 2023 | -221.88% |
| Jun 30, 2023 | -258.62% |
| Mar 31, 2023 | -320.00% |
| Dec 31, 2022 | -197.06% |
| Sep 30, 2022 | -196.97% |
| Jun 30, 2022 | -248.15% |
| Mar 31, 2022 | -377.78% |
| Dec 31, 2021 | 78.83% |
| Sep 30, 2021 | -824.17% |
| Jun 30, 2021 | -802.98% |
| Mar 31, 2021 | -767.29% |
| Dec 31, 2020 | -548.07% |
| Sep 30, 2020 | 2.82% |
| Jun 30, 2020 | -2,575.66% |
| Mar 31, 2020 | -1,585.89% |
| Dec 31, 2019 | -170.24% |
| Sep 30, 2019 | -1,256.86% |
| Jun 30, 2019 | -1,581.60% |
| Mar 31, 2019 | -985.09% |
| Dec 31, 2018 | -766.45% |
| Sep 30, 2018 | -247.63% |
| Jun 30, 2018 | -1,168.88% |
| Mar 31, 2018 | -1,018.24% |
| Dec 31, 2017 | -1,067.52% |
| Sep 30, 2017 | -14,192.64% |